| Mon, 15 Jul 2019 15:21:41: | Novartis offloads lagging endocrine drugs to Recordati for $390M
|
| Mon, 15 Jul 2019 14:42:42: | AstraZeneca's Farxiga follows rival Zynquista to FDA rejection in Type 1 diabetes
|
| Mon, 15 Jul 2019 14:27:29: | Indoco caught in maelstrom of FDA concerns as plant hit with warning letter
|
| Mon, 15 Jul 2019 14:03:11: | AbbVie's rising immunology star Skyrizi scores nod from England's cost watchdog
|
| Mon, 15 Jul 2019 14:01:45: | GSK's Zejula racks up first-line maintenance win in ovarian cancer, even in non-BRCA patients
|
| Sun, 14 Jul 2019 18:18:18: | Publicis debuts HealthFront with industry-specific take on Upfront and NewFront media events
|
| Fri, 12 Jul 2019 18:09:01: | Johnson & Johnson faces criminal probe over talc statements: report
|
| Fri, 12 Jul 2019 15:06:50: | Emgality maker Lilly courts payers with new migraine ER data
|
| Fri, 12 Jul 2019 14:37:33: | ICER deems unapproved Aimmune, DBV peanut allergy drugs unaffordable, sparking backlash
|
| Fri, 12 Jul 2019 14:21:05: | With test, Merck takes temperature-controlled drug delivery by drone from remote idea to remote locations
|
| Fri, 12 Jul 2019 14:05:34: | Thanks to patent win, Amgen ready to kick PCSK9 rivals Sanofi, Regeneron off the market in Germany
|
| Fri, 12 Jul 2019 11:58:22: | FiercePharmaAsia—J&J-Hanmi obesity breakup; BI-Yuhan NASH tie-up; GSK sites in China, Singapore
|
| Thu, 11 Jul 2019 22:42:36: | Gilead snags Lilly exec Shaw for Kite CEO position
|
| Thu, 11 Jul 2019 18:50:36: | Sanofi, Regeneron turn to photos, data plots to set Libtayo apart from I-O rivals
|
| Thu, 11 Jul 2019 14:33:21: | Alnylam recruits former Shire exec to replace departing CFO Soni
|
| Thu, 11 Jul 2019 14:21:59: | Indivior's former parent ponies up a whopping $1.4B to settle Suboxone marketing probe
|
| Thu, 11 Jul 2019 14:20:44: | Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
|
| Thu, 11 Jul 2019 13:53:03: | Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
|
| Thu, 11 Jul 2019 13:21:41: | Sterile drug maker Nexus launches $250M U.S. manufacturing project
|
| Thu, 11 Jul 2019 12:47:42: | Sorry, pharma: White House pulls industry's favored rebate proposal
|
| Wed, 10 Jul 2019 14:48:43: | Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
|
| Wed, 10 Jul 2019 14:25:13: | The hits keep coming: Apotex loses 31 drug approvals after FDA cites plants for 'inadequate' controls
|
| Wed, 10 Jul 2019 14:22:41: | GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?
|
| Wed, 10 Jul 2019 14:05:14: | Warning letter faults Akorn management for plant failures
|
| Wed, 10 Jul 2019 13:43:00: | FDA promises 'elevated' new drug approvals, but warns of potential pitfalls: report
|
